Shanghai Junshi Biosciences Co Ltd
HKEX:1877
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.3
36.84
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Shanghai Junshi Biosciences Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
S
|
Shanghai Junshi Biosciences Co Ltd
SSE:688180
|
35.9B CNY |
-40%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.8B USD |
33%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.3B USD |
34%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
154.2B USD |
39%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.9B USD |
39%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD |
28%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.5B AUD |
26%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
53.7B USD |
8%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR |
22%
|
Shanghai Junshi Biosciences Co Ltd
Glance View
Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. emerged as a dynamic player in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of innovative therapies. This company, based in Shanghai, China, has carved a niche in the highly competitive field through its robust pipeline of monoclonal antibodies, small molecule drugs, and therapeutic vaccines. Junshi Biosciences prides itself on its comprehensive R&D capabilities, operating state-of-the-art research facilities that foster significant scientific advancements. Central to its growth strategy is an ongoing commitment to addressing unmet medical needs in oncology, autoimmune, metabolic diseases, and beyond, positioning itself at the forefront of precision medicine. Junshi Biosciences generates revenue through a multifaceted business model that includes partnering with top-tier global pharmaceutical companies, engaging in strategic licensing agreements, and advancing its proprietary products through various stages of clinical trials to eventual market launch. A landmark achievement for the company was the development and commercialization of Toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody approved for multiple indications, which marked a significant milestone in its financial trajectory. Such breakthroughs not only bolster its top-line revenue but also solidify its reputation as an innovator in the global biotechnology landscape. By blending scientific ingenuity with strategic collaborations, Junshi continues to expand its international footprint and deepen its impact on global health.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Shanghai Junshi Biosciences Co Ltd's most recent financial statements, the company has Operating Margin of -40.4%.